Certara (NASDAQ:CERT) Trading Up 11.5% – Here’s What Happened
by Teresa Graham · The Cerbat GemShares of Certara, Inc. (NASDAQ:CERT – Get Free Report) rose 11.5% during trading on Thursday . The stock traded as high as $5.17 and last traded at $5.2050. Approximately 2,766,645 shares were traded during trading, a decline of 18% from the average daily volume of 3,370,438 shares. The stock had previously closed at $4.67.
Analysts Set New Price Targets
Several research firms have weighed in on CERT. BMO Capital Markets dropped their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. Barclays decreased their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Robert W. Baird lowered their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, May 12th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Finally, Wall Street Zen lowered Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.85.
Check Out Our Latest Research Report on Certara
Certara Stock Performance
The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. The stock has a market cap of $804.30 million, a P/E ratio of -51.70 and a beta of 1.53. The firm’s 50-day moving average is $5.87 and its two-hundred day moving average is $7.64.
Certara (NASDAQ:CERT – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. During the same period in the prior year, the firm earned $0.14 earnings per share. The business’s revenue was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, research analysts expect that Certara, Inc. will post 0.29 EPS for the current year.
Hedge Funds Weigh In On Certara
Several hedge funds have recently bought and sold shares of the business. Wasatch Advisors LP raised its holdings in Certara by 45.7% during the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after buying an additional 4,244,230 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Certara during the 4th quarter worth about $26,706,000. Deerfield Management Company L.P. increased its holdings in shares of Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock valued at $82,357,000 after acquiring an additional 2,813,438 shares during the last quarter. Bank of America Corp DE lifted its holdings in Certara by 292.2% in the 1st quarter. Bank of America Corp DE now owns 2,042,946 shares of the company’s stock worth $11,645,000 after purchasing an additional 1,522,034 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH lifted its holdings in Certara by 133.4% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock worth $20,024,000 after purchasing an additional 1,299,109 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.
About Certara
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company’s offerings are divided into software tools and consulting services.